Cargando…
Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology
The success of selective B-cells depleting therapies, as the anti-CD20 antibodies, in patients with multiple sclerosis (MS) has confirmed that B-cells are critical in the immune pathogenesis of the disease. Ocrelizumab, a humanized monoclonal antibody that selectively targets CD20+ B-cells, profound...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8331077/ https://www.ncbi.nlm.nih.gov/pubmed/34354358 http://dx.doi.org/10.2147/TCRM.S282390 |